Scienture Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
SCNX$3.04-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended December 31, 2025 and 2024
| Year Ended | ||||
|---|---|---|---|---|
| December 31, | ||||
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss from continuing operations | $(43,507,142) | $(18,778,876) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation expense | 2,000 | 2,000 | ||
| Amortization of intangible assets | 453,846 | - | ||
| Change in fair value of warrant liability | (909,020) | 182,982 | ||
| Change in fair value of derivative liability | (2,296,834) | (180,383) | ||
| Loss on conversion of note payable | 53,446 | - | ||
| Loss on disposition of subsidiaries | 214,486 | - | ||
| Stock-based compensation | 2,068,892 | 25,584 | ||
| Common stock issued for services | 4,310,090 | 4,598,294 | ||
| Goodwill impairment | 26,346,050 | - | ||
| Impairment of investment | - | 2,500,000 | ||
| Amortization of debt discount | 3,161,100 | 912,447 | ||
| Amortization of right-of-use assets | 35,935 | 51,361 | ||
| Interest income | (250,000) | - | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable, net | (720,222) | (11,106) | ||
| Prepaid expenses and deposits | (193,023) | 34,656 | ||
| Inventory | (213,408) | 968 | ||
| Other receivables | (80,469) | (2,914,068) | ||
| Lease liability | (36,979) | (51,587) | ||
| Accounts payable | (1,567,215) | 448,572 | ||
| Accrued liabilities | (248,574) | (44,616) | ||
| Current liabilities | (5,441) | (62,390) | ||
| Net cash used in operating activities from continuing operations | (13,382,482) | (13,286,163) | ||
| Net cash provided by (used in) operating activities from discontinued operations | 2,799 | (979,075) | ||
| Net cash used in operating activities | (13,379,683) | (14,265,239) | ||
| Cash flows from investing activities: | ||||
| Cash received in acquisition | - | 132,976 | ||
| Acquisition of property and equipment | - | (12,000) | ||
| Investment in securities | - | (2,500,000) | ||
| Net cash used in investing activities from continuing operations | - | (2,379,024) | ||
| Net cash provided by investing activities from discontinued operations | - | 29,931,815 | ||
| Net cash provided by investing activities | - | 27,552,791 | ||
| Cash flows from financing activities: | ||||
| Repayment of contingent liability | - | (1,246,346) | ||
| Proceeds from loan payable, related party | 116,000 | 150,000 | ||
| Repayment of loan payable, related party | (531,000) | - | ||
| Proceeds from issuance of convertible notes, net of issuance costs | - | 2,954,000 | ||
| Proceeds from convertible notes | 3,500,000 | - | ||
| Repayment of convertible notes | (9,244,444) | - | ||
| Gross proceeds from issuance of common stock | 26,293,039 | - | ||
| Repayment of development liability | (400,000) | - | ||
| Cash dividends paid | - | (14,858,831) | ||
| Proceeds from exercise of warrants | - | 16,567 | ||
| Proceeds from exercise of options | - | 9,840 | ||
| Net cash provided by (used in) financing activities from continuing operations | 19,733,595 | (12,974,770) | ||
| Net cash used in financing activities from discontinued operations | - | (5,000) | ||
| Net cash provided by (used in) financing activities | 19,733,595 | (12,979,770) | ||
| Net change in cash | 6,353,912 | 307,782 | ||
| Cash at beginning of period | 308,096 | 314 | ||
| Cash at end of period | $6,662,008 | $308,096 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | $ | - | $ | - |
| Cash paid for taxes | $ | - | $ | - |
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Conversion of note payable into common stock | $411,000 | $ | - | |
| Equity line of commitment shares issued as offering costs | $1,526,318 | $534,800 | ||
| Issuance of note receivable in exchange for other receivables | $5,000,000 | $ | - | |
| Issuance of shares pursuant to Merger | $ | - | $78,646,184 | |
| Assets acquired in connection with Merger | $ | - | $194,554 | |
| Liabilities assumed in connection with Merger | $ | - | $5,797,117 | |
| Insurance premium financed | $ | - | $198,245 | |
| Issuance of common shares in connection with converible debenture | $ | - | $420,200 | |
| Deferred offering costs | $ | - | $69,444 | |
| Derivative liability recognized in connection with issuance of convertible note | $ | - | $2,477,217 | |
| Warrants issued with convertible note | $ | - | $71,332 | |
| Common stock issued for convertible note settlement | $189,673 | $ | - | |
| Common stock issued for convertible note extension | $175,250 | $ | - | |
| Accretion of original issue discount on Treasury Bills | $20,625 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.